It is very uncertain whether preconception lifestyle advice on weight changes adverse events ‐ Hypertension compared with routine care or attention control (very low certainty).
Steroid therapy in first episode of nephrotic syndrome: five to… showed no clear difference in adverse events: hypertension compared with three months (moderate certainty).
Steroid therapy in first episode of nephrotic syndrome: 3 months or… showed no clear difference in adverse events: hypertension compared with 2 months of therapy (moderate certainty).
IV cyclophosphamide may leads to lower adverse events: hypertension compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
Low dose calcineurin inhibitors (CNI) showed no clear difference in adverse events: hypertension compared with to standard dose CNI (low certainty).
Calcineurin inhibitor (CNI) withdrawal + mammalian target of… showed no clear difference in adverse events: hypertension compared with standard dose CNI (low certainty).
Low dose CNI calcineurin inhibitor (CNI) + mammalian target of… showed no clear difference in adverse events: hypertension compared with standard dose CNI (low certainty).
Calcineurin inhibitor (CNI) withdrawal may leads to lower adverse events: hypertension compared with standard dose CNI (low certainty).
Epoetin alfa every four weeks showed no clear difference in adverse events: hypertension compared with with every two weeks (moderate certainty).
Epoetin theta showed no clear difference in adverse events: hypertension compared with epoetin beta (moderate certainty).
Epoetin alpha every 2 weeks showed no clear difference in adverse events: hypertension compared with to weekly (moderate certainty).
Corticosteroid leads to lower adverse events ‐ hypertension compared with control (high certainty).
Apatinib plus chemotherapy or chemotherapy/brachytherapy may leads to higher specific adverse events: hypertension compared with chemotherapy or chemotherapy/brachytherapy (low certainty).
Pazopanib plus lapatinib probably leads to higher specific adverse events: hypertension compared with lapatinib (moderate certainty).
Pazopanib probably leads to higher specific adverse events: hypertension compared with lapatinib (moderate certainty).
Bevacizumab plus chemotherapy probably leads to higher specific adverse events: hypertension compared with chemotherapy (moderate certainty).
It is very uncertain whether cyclosporin changes adverse events: worsening of hypertension compared with placebo or no treatment (very low certainty).
It is very uncertain whether oral cyclophosphamide changes adverse events: hypertension with seizures compared with prednisone or placebo (very low certainty).
It is very uncertain whether cediranib plus chemotherapy changes specific adverse events: serioushypertension compared with placebo plus chemotherapy (very low certainty).